EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐ cell subsets and immunophenotypes in cancer patients

Ahmed M Salem iD, Ganesh M Mugundu, Aman P Singh iD

CPT: Pharmacometrics & Systems Pharmacology · 2023-09 · 12 (9) · 1285-1304

DOI: 10.1002/psp4.13009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 18.08.2023. Verfasst von Ahmed M Salem und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Modeling, Precision and Translational Medicine, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceuticals, Ca…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell subsets and immunophenotypic composition of the pre‐infusion product, as well as their longitudinal changes following infusion, are expected to affect CAR T‐cell expansion, persistence, and clinical outcomes. Herein, we sequentially evolved our previously described cellular kinetic‐pharmacodynamic (CK‐PD) model to incorporate CAR T‐cell product‐associated attributes by utilizing published preclinical and clinical datasets from two affinity variants (FMC63 and CAT19 scFv) anti‐CD19 CAR T‐cells. In step 1, a unified cell‐level PD model was used to simultaneously characterize the in vitro killing datasets of two CAR T‐cells against CD19+ cell lines at varying effector:target ratios. In step 2, an augmented CK‐PD model for anti‐CD19 CAR T‐cells was developed, by integrating CK dataset(s) from two bioanalytical measurements (quantitative polymerase chain reaction and flow cytometry) in patients with cancer. The model described the differential in vivo expansion properties of CAR T‐cell subsets. The estimated expansion rate constant was ~1.12‐fold higher for CAR+CD8+ cells in comparison to CAR+CD4+ T‐cells. In step 3, the model was extended to characterize the disposition of four immunophenotypic populations of CAR T‐cells, including stem‐cell memory, central memory, effector memory, and effector cells. The model adequately characterized the longitudinal changes in immunophenotypes post anti‐CD19 CAR T‐cell infusion in pediatric patients with acute lymphocytic leukemia. Polyclonality in the pre‐infusion product was identified as a categorical covariate influencing differentiation of immunophenotypes. In the future, this model could be leveraged a priori toward optimizing the composition of CAR T‐cell infusion product, and further understand the CK‐PD relationship in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansChildKineticsT-Lymphocyte SubsetsImmunotherapy, AdoptiveAntigens, CD19Receptors, Antigen, T-Cell

Substanzen

Receptors, Chimeric AntigenAntigens, CD19Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Clinical Pharmacology and Modeling, Precision and Translational Medicine, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

ORCID-Profile: Ahmed M Salem, Aman P Singh

Zitieren

APA

Salem, A. M., Mugundu, G. M., & Singh, A. P. (2023). Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐ cell subsets and immunophenotypes in cancer patients. CPT: Pharmacometrics & Systems Pharmacology, 12(9), 1285-1304. https://doi.org/10.1002/psp4.13009

Vancouver

Salem AM, Mugundu GM, Singh AP. Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐ cell subsets and immunophenotypes in cancer patients. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(9):1285-1304. doi:10.1002/psp4.13009

BibTeX
@article{Salem2023,
  author = {Salem, Ahmed M and Mugundu, Ganesh M and Singh, Aman P},
  title = {Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐ cell subsets and immunophenotypes in cancer patients},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  volume = {12},
  number = {9},
  pages = {1285--1304},
  doi = {10.1002/psp4.13009}
}
Kostenlos starten →